Founder, CEO and Chairman
As Founder/CEO, Eric has built eight biopharmaceutical, drug delivery and medical device companies. His success is based on the consistent theme of recognizing early breakthrough scientific concepts and their commercial applications. He has personally invested, developed, and executed profoundly impactful development, market, and growth strategies. Emerging from his experience is a tested, repeatable model for establishing the strategy, key resources, infrastructure, relationships, and financing to enable rapid commercialization, scaling and growth. He has managed multiple products through FDA marketing approval or clearance. He has raised $138M from venture, angel, and family office sources, $101M from two IPOs and $660M+ in strategic pharmaceutical company collaborations. Cumulative post money valuations following financings exceeded $1.7B. Investor exits on six closed transactions averaged 8.3 times paid-in capital. Two companies reached annual revenues of $500+ and $800+ million under his tenure.
Eric was an original coauthor of the National Childhood Injury Compensation Act of 1986, a no-fault alternative to the traditional tort system to provide compensation to people injured by certain pediatric vaccines. His initial financial risk sharing models led to the creation of the Vaccine Manufacturers Assoc., teaming with Senators Arlen Spector and Ted Kennedy, and ultimately placing the necessary vaccine industry protections to enable capital investment, research, development and free broad scale pediatric vaccine distribution to inner cities and rural America, including the primary solution to fulfill the National Vaccine Stockpile. Through 2020, over $4.5B in compensation has been paid out and an industry now flourishes.
Over 35 years, he has co-initiated, driven and managed through full development and/or full global commercialization startup companies in behavioral healthcare (Atentiv); in pediatric, adult and traveler’s vaccines (Connaught Labs -IPO -now Sanofi-Pasteur, and Virogenetics-acquired); in combinatorial chemistry for drug discovery (ArQule – IPO – Merck acquired); in clinical genomics (Ardais – sold); in drug-delivery for endometriosis and PCOD (Combinent); in HDL/CHD therapeutics (Cardium – sold); and ADHD diagnostics (BioBehavioral Diagnostics – sold).
He began his career with Arthur Andersen & Co. and served as VP and CFO at Sterling Drug and General Manager at Glenbrook Labs. Eric holds business degrees from Syracuse University, the University of Pennsylvania, The Wharton School and is a CPA.
Eric is a father of a child with severe ADHD, finding a safe and effective solution, has been a primary focus for over a decade.
Barry K. Herman, M.D., M.M.M
Chief Medical Officer
Barry K. Herman, M.D., MMM is a dual Board-Certified Psychiatrist in both Child & Adolescent Psychiatry and Adult Psychiatry with 35 years of medical executive experience in the pharmaceutical industry and clinical practice. He has a track record of success in building and leading global teams, developing and executing strategic medical plans, overseeing clinical development programs, supporting commercial launches, and managing product life cycle, Most recently he was Sr. Vice President and Chief Medical Officer of Tris Pharma, Inc (ADHD). Prior to Tris Pharma, Inc., he held leadership positions at Pfizer, Inc., Sanofi, Sunovion, Shire, and Ironshore Pharmaceuticals. At Shire, Dr. Herman led medical affairs in expanding the Vyvanse (ADHD) portfolio.
Dr. Herman is a Distinguished Life Fellow of both the American Psychiatric Association (APA) and the American Academy of Child and Adolescent Psychiatry (AACAP). He is the author of over 100 scientific abstracts and publications. Dr. Herman is the recipient of the 2017 American Psychiatric Association Award in Administrative Psychiatry.
Dr. Herman received his Bachelor’s Degree from Clark University, received his Medical Degree from Tufts University School of Medicine, and completed a Fellowship in Child and Adolescent Psychiatry at Stanford University School of Medicine. He received a Masters Degree in Medical Management from Tulane University School of Public Health and Tropical Medicine.
Chief Commercial Officer
Chris Saunders is an innovative leader with a 20+ year track record of successful commercialization of novel biopharmaceuticals from the end of Phase 2 through launch and beyond. His passion for understanding the customer then driving innovative strategies is evident from the Vioxx launch as a sales rep for Merck to multiple ADHD launches (Daytrana, Intuniv) at Shire and especially by his Go-to-Market strategy at Shire that drove the success for the US launch of the Binge Eating Disorder indication for Vyvanse. He then went on to lead the US commercial team for the neuroscience portfolio (>$2B: Vyvanse, Adderall & Instuniv for ADHD).
While at the digital therapeutic company, Akili Interactive, Chris built the marketing function from scratch by identifying top talent to create a high performing team with a culture of excellence. He strove to deliver superior results with limited resources using an agile approach.
Chris earned his BS in Mechanical Engineering at Lafayette college and holds an MBA from Emory University, The Goizueta School of Business.
VP – Systems Development and Operations
Shane is a serial entrepreneur having conceived and managed IT service platforms through commercialization and to multiple exits, particularly in gaming and health IT. He has 20 years of experience in leading large scale strategic initiatives, product and software development, digital media, gaming, health IT, SaaS, IoT, banking within global and start up environments. Most recently, he sold his gaming operational and business platform company, Knetik, to CMA Group. Other prior technology exits include, Trust Hub, Splyt Analytics, PHXX OTT Platform, Row Sham Bow, Data Warehouse, V2R Group, Red Lambda and ICU Data Systems. Shane started his career as Command Control Specialist for the US Air Force developing flight traffic control systems.
Shane holds a BS Science and Engineering from University of Central Florida and completed USAF Officer Candidate School
Vice President – Collaborative Care
Suzanne Mitchell, M.D., M.S. specializes in family medicine, primary, behavioral, ambulatory and palliative health care. Her career has concentrated on healthcare communications and education that enable care transition program design and implementation, quality, services, delivery, medical home and integration of behavioral care. She specializes in workflow analysis, role and responsibility assessment, team-based training, population health analysis and value-based payment strategies. She is an expert in health behavior counseling and shared decision making in medical settings, including educational product development, workshop production and live trainings. In this capacity, she has been engaged by Commonwealth Care Alliance, Merck & Co, Health Management Associates Inc, Disparities Solution Center at Massachusetts General Hospital, Geisinger Health System, Sutter Health of California, North Shore Elder Services (PACE), Senior Link of Massachusetts, California Board of Family Medicine, Greater New York Hospital Association, and United Hospital Fund.
She obtained an MD from Wake Forest School of Medicine, MS from the University of California, and BS from Bentley College, Cum Laude. She completed a Family Medicine Residency at White Memorial Medical Center and an Academic Medicine Fellowship, Department of Family Medicine, Boston University School of Medicine.
Marcia A. Kean is Chairman, Strategic Initiatives, Feinstein Kean Healthcare. Marcia Kean has built Feinstein Kean Healthcare’s unique national role as a strategy and communications consultancy in the life sciences and healthcare since the firm’s inception 25+ years ago. She served as the Chief Executive Officer of the firm from 2002 to 2011, and became Chairman, Strategic Initiatives in 2011. Throughout her career, Marcia has stood alongside innovators whose disruptive technologies and ideas have transformed the landscape of biomedicine. She has counseled dozens of senior management teams in corporate positioning and product communications, crisis communications, investor relations, and constituency-building. Her clients have included Big Pharma companies; start-ups in biopharma, device, informatics, personal health and clinical decision support; policy organizations; academic/medical centers; patient advocacy groups; and federal government agencies. Marcia was a member of the Board of Trustees of the MFS Compass Funds from 2005 to 2011, and served as chair of that Board’s Governance and Compliance Committee.
Marcia holds an M.B.A. in finance from New York University and a B.A. from the University of California at Berkeley.
Martha C. Farmer, PhD, is the Founder of North Shore InnoVentures, a non-profit business incubator in Beverly, MA, that is the 2018 winner of the “Dinah Adkins Technology Incubator of the Year” award from the International Business Innovation Association (InBIA). The incubator is dedicated to innovation, entrepreneurship, and economic development through fostering life sciences and cleantech start-ups.
She currently serves on the Board of Advisors and on the Institutional Review Board of Endicott College and on the Ethics Committee of Northeast Hospital Systems. She is on the Boards of Directors of the North Shore Technology Council and the Life Sciences Consortium of the North Shore and on various Advisory Boards.
Her biotech industry career began with the launch of Baxter Healthcare’s Hemoglobin Therapeutics Division in 1987, which she helped grow from 3 people to 130 over ten years. Subsequently, Dr. Farmer co-founded the radiopharmaceutical start-up, BetaGamma LLC. She earned a BS in zoology and a PhD in physiology and pharmacology from Duke University, did postdoctoral training at Johns Hopkins University and the Naval Research Laboratory and was a Medical Ethics Fellow at Harvard University. She is an author on more than 30 publications and three patents.
John L. Brooks III is the Managing Director of Healthcare Capital LLC, which advises early-stage life sciences companies. Mr. Brooks is on the board of a number of for-profit and not-for-profit organizations, and he recently managed as CEO a biotechnology reverse merger.
Mr. Brooks is the former President & Chief Executive Officer and Chairman of the Joslin Diabetes Center, a Boston based diabetes research, clinical care, and education organization.
Mr. Brooks is a well-known life sciences executive. He has co-founded seven life sciences companies. He was a co-founder of Prism Venture Partners, a $1.25B venture capital firm.
Prior to that, Mr. Brooks was a senior medical device executive at Pfizer, and a senior manager at Arthur Andersen & Co. in Boston, MA, where he focused on early stage companies.
A native of Massachusetts, he holds an M.S. in Business Administration and a B.B.A. cum laude from the University of Massachusetts at Amherst and he is a Certified Public Accountant.
Steve Gullans, Ph.D., is an experienced biotech executive, venture investor, scientist, entrepreneur, and author. He currently advises life science companies on strategy. Previously he was CEO of Gemphire Therapeutics, Inc., a public biotech which he joined after 10 years as a Managing Director at Excel Venture Management (EVM), a firm he co-founded and which has invested $225M across more than 40 life science companies. At Excel, Steve served as a Board Director of more than a dozen private and public biotech, medtech, diagnostics, and health IT companies with many successful exits. Prior to Excel, Steve held CEO and CSO positions at two life sciences companies. Steve is currently a Director at Orionis Biosciences and iSpecimen.
Steve began his career as a professor at Harvard Medical School and Brigham & Women’s Hospital where he published more than 130 scientific papers and was elected a Fellow of the American Association for the Advancement of Science and of the American Heart Association. He was an advisor to the Innovation Groups at the Cleveland Clinic and the Mass General Brigham. He received his Ph.D. from Duke University, post-doctoral training at Yale University, and his B.S. from Union College.
Steve loves innovation and has spoken widely, including at TED, TEDMED, and TEDx. With Juan Enriquez he co-authored Evolving Ourselves, a book that provides a sweeping tour of how humans are changing the course of evolution. Throughout his career he has focused on translating scientific advances into solutions for patients.
Consultant – Clinical Practices
Dr. Hallowell is a child and adult psychiatrist and the founder of The Hallowell Center for Cognitive and Emotional Health in Sudbury, MA and New York City. Dr. Hallowell is considered to be one of the foremost experts on the topic of ADHD and is a highly recognized speaker around the world. He has presented to thousands on topics such as ADD strategies on handling your fast paced life, the Childhood Roots of Adult Happiness and other pertinent family and health issues. He has been prominently featured in the media including 20/20, Oprah, CNN, PBS and NPR as well as 60 Minutes, The Today Show, Dateline, Good Morning America, US News and World Report, Newsweek, the Harvard Business Review and the New York Times. He is the co-author, with Dr. John Ratey, of Driven to Distraction and Answers to Distraction, which have sold more than a million copies. In 2005, Drs. Hallowell and Ratey released their much-awaited third book on ADHD, Delivered from Distraction. He was a member of the faculty of the Harvard Medical School from 1983 to 2004 until he retired to devote his full professional attention to his clinical practice, lectures, and the writing of books.
Dr. Hallowell is a graduate of Harvard College and Tulane School of Medicine.
Consultant, Quantitative Electroencephalography
Dr. Krystal is Professor, Psychiatry and Behavioral Science, UCSF,
Executive Vice-Chair, Langley Porter Psychiatric Institute, UCSF
Director, Sleep Research Program, UCSF; Mood Disorders Program, UCSF
Ray and Dagmar Dolby Distinguished Professor of Psychiatry, UCSF.
His research is focused on mood disorders following 30 years of treating patients with mood disorders. His work includes: identifying EEG indices that can be used to improve the clinical dosing of electroconvulsive therapy (ECT) for patients with treatment-resistant depression; carrying out pivotal trials of repetitive transcranial magnetic stimulation (rTMS) as a treatment for major depression; carrying out a pivotal trial of the antidepressant effects of transcranial direct current therapy (tDCS); completing trials evaluating whether cognitive behavioral therapy and pharmacotherapy for insomnia augment the antidepressant response to SSRI and SNRI medications; completing studies developing physiologic biomarkers that are predictors and correlates of the response to the rapidly acting antidepressant ketamine, and cognitive behavioral therapy in depressed patients; serving as overall PI of the NIMH Contract “New Experimental Medicine Studies: Fast-Fail Trials in Mood and Anxiety Spectrum Disorders (FAST-MAS.)”Also leads a a multi-site team in carrying out trials of promising new therapies for mood and anxiety spectrum disorders using novel neuroscience-based early phase methodologies.
Dr. Krystal completed his medical training at Duke University School of Medicine. Dr. Krystal also completed a residency in Psychiatry, his Clinical Research Methodology and a fellowship in Clinical Neurophysiology at Duke University Medical Center.
Consultant, Clinical Practices
John J. Ratey, MD, is an Associate Clinical Professor of Psychiatry at Harvard Medical School, Research Synthesizer, Speaker, and best selling Author. He has published over 60 peer-reviewed articles on the topics of Aggression, Autism, ADHD, and other issues in Neuropsychiatry, and written 8 books published in 14 languages. Dr. Ratey is the co-author of the ground breaking ADD-ADHD series of books, “Driven to Distraction,” “Answers to Distraction,” and “Delivered from Distraction,” with Edward Hallowell, MD. First published in 1994, “Driven to Distraction” is still considered the seminal book on ADD-ADHD, and to this day remains a best seller in the field.
In addition, Dr. Ratey is the author of “A Users Guide to the Brain” (2000) and co-author of “Shadow Syndromes” (1997) with Catherine Johnson, PhD., both published by Pantheon/Random House. He has edited several academic publications, including “The Neuropsychiatry of Personality Disorders”(1994), published byBlackwell Scientific. Consistently named one of the Best Doctors in America by his peers, Dr. Ratey and his work are frequently profiled in the media, where he’s been featured on ABC, CBS, NBC, PBS and NPR, and well as in The New York Times, Newsweek, The Washington Post, US News and World Report, Forbes, Men’s Health, Fitness Magazine, and other national publications.
Dr. Ratey maintains a private practice in Cambridge, Massachusetts, and recently completed and published by Little Brown a new book examining our genetic roots and the influence on our psychology in a modern world, titled, “Go Wild.”
Dr. Wagner has served as co-director of the Change Leadership Group (CLG) at the Harvard Graduate School of Education since its inception in 2000. An initiative of the Bill & Melinda Gates Foundation, CLG is a knowledge-development and capacity-building organization focused on helping teens become effective change leaders in school and district improvement. He was also on the faculty of the Executive Leadership Program for Educators, a joint initiative of Harvard’s Graduate School of Education, Business School, and Kennedy School of Government. Dr. Wagner consults widely to public and independent schools, districts, and foundations around the country and internationally, and served as Senior Advisor to the Bill & Melinda Gates Foundation for eight years. Dr. Wagner’s publications include numerous articles and four books: The Global Achievement Gap: Why Even Our Best Schools Don’t Teach the New Survival Skills Our Children Need, And What We Can do About It; Change Leadership: A Practical Guide to Transforming Our Schools; Making the Grade: Reinventing America’s Schools; and How Schools Change: Lessons from Three Communities Revisited. Dr. Wagner’s latest book is Creating Innovators: The Making of Young People Who Will Change The World.
Having worked for more than 35 years in the field of school improvement, Dr. Wagner is a frequent keynote speaker and widely published author on education and society. Prior to assuming his current position at Harvard, he was a high school teacher for 12 years, a school principal, a university professor in teacher education, co-founder and first executive director of Educators for Social Responsibility, project director for the Public Agenda Foundation in New York, and President and CEO of the Institute for Responsive Education.
He earned a Ph.D. in education at Harvard University.
Thank you for your interest in the ATENTIVmynd™ Solution.